Premier Strategy & Business Development Services
for the Biotech & Pharmaceutical Industries
Core Services
CBOs perform a critical strategic function when it comes to planning and partnering. Many companies do not need a full-time CBO or are carefully managing funds. The fractional CBO function can integrate with other functions to make strategic decisions, seek external partners, or evaluate other strategic considerations.
Most companies will need a Business Development (BD) function. Whether searching for assets, evaluating opportunities, performing valuations, negotiating deals, or managing an alliance, BD is a critical function. A mistake in BD can make or destroy the future of a company; getting the right talent and support is paramount. Some companies won’t have the right experience on hand, others can be overwhelmed during a busy time, and some would like a 3rd party opinion to support an expensive transaction. Access and relationships to the right people can win a deal, performing the proper valuation to ensure value and terms are correct, and communicating the story with appropriate understanding of benefits and risks is a requirement for success.
CEOs and other officers have a very difficult task of setting strategic direction and making the tough calls. While no one has all of the answers, it helps to have an independent expert with an outside perspective to think through critical issues and avoid the blind spots. Whether creating a strategic plan, putting together a board deck, considering a strategic transaction, performing diligence or dealing with a difficult partner, having access to trusted expertise makes the difference in getting it right.
About the Company
Founder & CEO, Michael Pine has over 25 years of industry experience, completing >60 deals . After successfully exiting his role as CBO at EyePoint Pharmaceuticals, Michael founded Pine Health Strategies in response to a large, unmet need for premier Business Development support from many friends and former colleagues in senior roles at companies. His education and training at Cornell, Columbia, MIT and JP Morgan enables him to problem solve using management consulting and qualitative/quantitative analytical skills. He excels at breaking down challenging questions into basic elements, analyzing and weighing benefits and risks to clarify and arrive at the best possible decisions.
Resume Highlights
Relevant Experience:
EyePoint Pharmaceuticals, CBO
Medexus Pharmaceuticals, SVP Business Development & Strategy
Lupin Pharmaceuticals, SVP Business Development & Licensing - Global Specialty Products
Aralez Pharmaceuticals, VP, Head of Corporate Development & Licensing
Novartis:
Director, Head of Strategy, Operations & Analytics
Director, Market Access & Strategy (Leadership Development Program)
Director, Brand Marketing & Alliance Management (Leadership Development Program)
Director, US Business Development & Licensing
Kos Pharmaceuticals, Director, Corporate Development & Strategy (sold to Abbvie)
Organon International , Director, Global Business Development (now Merck)
Pfizer: Sr. Manager, New Product Development Licensing & Acquisitions
Wyeth: Brand Management Intern
JP Morgan: Investment Banking Senior Financial Analyst
Financial World Magazine: Intern, Reporter
Education:
MBA, Columbia Business School
BS, Cornell University
Transaction Highlights
Completed 60+ transactions across therapeutic areas, stages of development and deal structure
Conducted financial analysis, deal terms for billions of value for Pfizer including Rebif® (Serono) and Macugen® (Eyetech)
Recommendation and divestiture of commercial products of EyePoint to transform company into Biotech ($83M)
In-licensed Grafapex® for Medexus in 2021; approved 2025 (~$100M)
Identified and negotiated 4 co-promotions of approved products for Novartis over a 2 year period
Financial modeling and execution of four high yield debt offerings across industries (~$1B)
Competitive Advantage
-
Extensive network developed over 25 years provides access to BD and/or senior management at most companies; 5,000+ connections on LinkedIn, active at major conferences like Bio and JPM, engaged with many board members and VCs throughout industry
-
Unparalleled financial modeling skills built as an investment banker and Columbia Business School, with outputs that measure and account for risk. Developed “real options” eNPV model with MIT professor while at Pfizer; excel guru but can translate results into clear, concise story with appropriate scenarios presented. Changed how deals were done in industry starting in 2001.
-
Outside of BD/Strategy, key insights and skills developed while working as a banker, as a Director of Brand Marketing, a Director of Strategic Market Access (managed markets) and the head of operations and analytics. Key area of differentiation that enables challenging assumptions, finding hidden value, avoiding pitfalls, and accuracy of forecasts.
-
Deep training and experience in negotiation planning and execution; routinely finding issues and opportunities not seen by attorneys. Nothing replaces experience here as it’s not just tactics; it’s being able to predict the chess board before the game starts. It’s understanding partner motivations and how to create the win-win scenarios that enable deals to go through. It’s navigating through a narrow passage and finding creative solutions when there are no obvious ones available. And it’s knowing when to walk by eliminating emotion from the decision.
Contact Us
Interested in working together? Email us directly at mpine@pinehealthstrategies.com or provide your basic information and we will be in touch shortly.